Monday, February 24, 2025 8:43:59 AM
Once again you’ve wasted your time on an absolutely worthless post. Great job.
The problem with the Advent/NWBO relationship is not who owns the tech, who pulls the strings, what Advent is or isn’t allowed to do.
The problem is the conflict of interest.
NWBO (Linda Powers) is paying Advent (Linda Powers) in shares. So Linda is paying Linda. If Linda Powers believes as we do that the share price is going to go up dramatically, she has real and huge motivation to artificially suppress the share price as long as she can while paying out Advents milestones in shares. If she thinks the market cap is going to get to $10B she would be much richer giving Advent (herself) 100 million shares at $.25 instead of 25 million shares at $1.00. About $300-400 million richer to be precise. Therefore she has plenty of motivation and the means to artificially suppress the share price at the expense of shareholders.
And it can be said with almost absolute certainty that is what she is doing.
The problem with the Advent/NWBO relationship is not who owns the tech, who pulls the strings, what Advent is or isn’t allowed to do.
The problem is the conflict of interest.
NWBO (Linda Powers) is paying Advent (Linda Powers) in shares. So Linda is paying Linda. If Linda Powers believes as we do that the share price is going to go up dramatically, she has real and huge motivation to artificially suppress the share price as long as she can while paying out Advents milestones in shares. If she thinks the market cap is going to get to $10B she would be much richer giving Advent (herself) 100 million shares at $.25 instead of 25 million shares at $1.00. About $300-400 million richer to be precise. Therefore she has plenty of motivation and the means to artificially suppress the share price at the expense of shareholders.
And it can be said with almost absolute certainty that is what she is doing.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
